Brief: Tracon Pharmaceuticals Announces Results Of Independent Data Monitoring Committee Review Of Safety Data From Envasarc Pivotal Trial
10/08/2022 14:40
Aug 10 (Reuters) - TRACON Pharmaceuticals Inc TCON.O :
* TRACON PHARMACEUTICALS INC ANNOUNCES RESULTS OF
INDEPENDENT DATA
MONITORING COMMITTEE REVIEW OF SAFETY DATA FROM ENVASARC PIVOTAL
TRIAL
* TRACON PHARMACEUTICALS INC - INDEPENDENT DATA MONITORING
COMMITTEE FOR THE ENVASARC PIVOTAL TRIAL HAS RECOMMENDED THAT
THE TRIAL PROCEED AS PLANNED
Source text for Eikon: ID:nGNXbjsQwg
Further company coverage: TCON.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on TRACON Pharmaceuticals
See all newsBrief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Brief: Tracon Pharmaceuticals Files For Offering Of Common Stock, Pre-Funded Warrants